It is a single-center, open-label, Phase I clinical study evaluating the safety and pharmacokinetics of a single oral TPN171H in elderly subjects.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
12
5 mg TPN171H tablets,single dose,oral
Shanghai Xuhui Central Hospital
Shanghai, Shanghai Municipality, China
Adverse events
Number of Participants With treatment-related Adverse Events and Serious Adverse Events
Time frame: 7 days after dosing
Pharmacokinetic parameter of TPN171H:Tmax
Pharmacokinetic parameter of TPN171H:Tmax
Time frame: 48 hours after dosing
Pharmacokinetic parameter of TPN171H:Cmax
Pharmacokinetic parameter of TPN171H:Cmax
Time frame: 48 hours after dosing
Pharmacokinetic parameter of TPN171H:T1/2
Pharmacokinetic parameter of TPN171H:T1/2
Time frame: 48 hours after dosing
Pharmacokinetic parameter of TPN171H:AUC0-t
Pharmacokinetic parameter of TPN171H:AUC0-t
Time frame: 48 hours after dosing
Pharmacokinetic parameter of TPN171H:AUC0-∞
Pharmacokinetic parameter of TPN171H:AUC0-∞
Time frame: 48 hours after dosing
Pharmacokinetic parameter of TPN171H:AUC0-24h
Pharmacokinetic parameter of TPN171H:AUC0-24h
Time frame: 48 hours after dosing
Pharmacokinetic parameter of TPN171H:Ke
Pharmacokinetic parameter of TPN171H:Ke
Time frame: 48 hours after dosing
Pharmacokinetic parameter of TPN171H:Vd
Pharmacokinetic parameter of TPN171H:Vd
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 48 hours after dosing
Pharmacokinetic parameter of TPN171H:MRT
Pharmacokinetic parameter of TPN171H:MRT
Time frame: 48 hours after dosing
Pharmacokinetic parameter of TPN171H:CL/F
Pharmacokinetic parameter of TPN171H:CL/F
Time frame: 48 hours after dosing
Pharmacokinetic parameter of TPN171H:BRPP
Pharmacokinetic parameter of TPN171H:BRPP
Time frame: 48 hours after dosing